The Association between Presence of Comorbidities and COVID-19 Severity: A Systematic Review and Meta-Analysis

Author:

Honardoost MaryamORCID,Janani Laila,Aghili Rokhsareh,Emami Zahra,Khamseh Mohammad E.

Abstract

<b><i>Aim:</i></b> Several studies reported the accompaniment of severe COVID-19 with comorbidities. However, there is not a systematic evaluation of all aspects of this association. Therefore, this meta-analysis aimed to assess the association between all underlying comorbidities in COVID-19 infection severity. <b><i>Methods:</i></b> Electronic literature search was performed via scientific search engines. After the removal of duplicates and selection of articles of interest, 28 studies were included. A fixed-effects model was used; however, if heterogeneity was high (<i>I</i><sup>2</sup> &#x3e; 50%) a random-effects model was applied to combine the data. <b><i>Results:</i></b> A total of 6,270 individuals were assessed (1,615 severe and 4,655 non-severe patients). The median age was 63 (95% confidence interval [CI]: 49–74) and 47 (95% CI: 19–63) years in the severe and non-severe groups, respectively. Moreover, about 41% of patients had comorbidities. Severity was higher in patients with a history of cerebrovascular disease: OR 4.85 (95% CI: 3.11–7.57). The odds of being in a severe group increase by 4.81 (95% CI: 3.43–6.74) for a history of cardiovascular disease (CVD). This was 4.19 (95% CI: 2.84–6.19) for chronic lung disease and 3.18, 95% CI: 2.09–4.82 for cancer. The odds ratios of diabetes and hypertension were 2.61 (95% CI: 2.02–3.3) and 2.37 (95% CI: 1.80–3.13), respectively. <b><i>Conclusions:</i></b> The presence of comorbidities is associated with severity of COVID-19 infection. The strongest association was observed for cerebrovascular disease, followed by CVD, chronic lung disease, cancer, diabetes, and hypertension.

Publisher

S. Karger AG

Subject

Cardiology and Cardiovascular Medicine,Neurology (clinical),Neurology

Reference8 articles.

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.

2. Brown SM, Dean NC. Defining severe pneumonia. Clin Chest Med. 2011;32(3):469–79.

3. Liguoro I, Pilotto C, Bonanni M, Ferrari ME, Pusiol A, Nocerino A, et al. SARS-COV-2 infection in children and newborns: a systematic review. Eur J Pediatr. 2020;179(7):1029–46.

4. Zhang JJ, Lee KS, Ang LW, Leo YS, Young BE. Risk factors of severe disease and efficacy of treatment in patients infected with COVID-19: a systematic review, meta-analysis and meta-regression analysis. Clin Infect Dis. 2020 Nov 19;71(16):2199–206.

5. Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, et al. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet. 2020;395(10228):e52.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3